Our CEO David Reynolds speaks with Stephen Adams of Optimum Strategic Communications in the latest episode of #OptimumTV! In his conversation with Stephen, David provides insight into Huntington’s disease and the development of our oral small molecule drug that can block somatic expansion to slow or halt disease progression. Having recently announced our Series A financing from Forbion, SV Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF), David discusses how their support will be crucial in developing our pipeline. ?? Watch the full episode below to find out more and hear the story behind the name LoQus23. Follow LoQus23 Therapeutics Ltd on LinkedIn to stay up to date with our latest progress. #Huntingtonsdisease #SeriesA #drugdevelopment?
?? Huntington’s disease is a rare – but not that rare – inherited, neurological condition causing debilitating movement disorders, psychiatric problems and, ultimately, death. ? Cambridge-based LoQus23 Therapeutics Ltd, which is developing a disease-modifying treatment for the condition, has secured ￡35m in a #SeriesA round led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund?and Novartis Venture Fund. ? Watch LoQus23’s CEO David Reynolds talk about its approach in our latest edition of #OptimumTV.